# Nausea and the longer record

> Tolerability matters to The Peptide Woman — The Peptide Woman examines nausea, flushing, headache and cardiovascular cautions in the bremelanotide record, alongside its limited benefit.

Being attentive to a desired effect also means being attentive to the experience of continuing treatment.

## The extension study

In the [52-week open-label RECONNECT extension](https://pubmed.ncbi.nlm.nih.gov/31599847/), 684 women enrolled. Desire improvements were sustained and the report found no new safety signals. The most common drug-related treatment-emergent adverse events were nausea at 40.4%, flushing at 20.6% and headache at 12.0%.

“Open-label” means the treatment was known. That design gives the longer record a different basis from the [randomized comparison in the original trials](https://pubmed.ncbi.nlm.nih.gov/31599840/). I appreciate the additional follow-up while resisting the temptation to read “no new safety signals” as a description of an uneventful experience.

Nausea was the principal tolerability issue in the report. Its prominence deserves the same unhurried attention as the desire result. A rushed account of nausea makes me question whose experience is being taken seriously.

## Cardiovascular cautions

The [US prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9) warns of a transient increase in blood pressure and lists uncontrolled hypertension or cardiovascular disease as contraindications. A contraindication is a circumstance in which the medicine is ruled out under the label.

Those cautions make the body around the intended effect impossible to ignore. A desire score cannot answer a cardiovascular question. For the argument on this site, that is enough reason to give the warning a place of its own instead of compressing it into an adjective such as “safe.”

![Illustrated portable blood-pressure recorder beside an open arm cuff and its connecting tube.](images/pressure-recorder.webp)

*An imagined equipment illustration. The [prescribing information](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9) supports the cardiovascular cautions discussed here.*

## The judgement about carrying on

The [review describing limited efficacy](https://doi.org/10.1177/10600280241253273) also calls attention to adverse effects. Read beside the [extension findings](https://pubmed.ncbi.nlm.nih.gov/31599847/), that is a concrete reason to discuss the size of a benefit and the burden accompanying it together.

An individual's judgement is beyond these pages. This site's argument ends with an insistence on attention: attention to the concern, to the measured change and to the unwanted experience. That is a demanding enough standard without pretending every entry points toward medication.

---

I argue here about published research on women's sexual health; these pages provide neither medical advice nor clinical services nor commercial offerings.